FY2024 EPS Estimates for Immunic Lowered by Analyst

Immunic, Inc. (NASDAQ:IMUX) – Investment analysts at Brookline Capital Management dropped their FY2024 EPS estimates for shares of Immunic in a research note issued to investors on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian now expects that the company will earn ($0.89) per share for the year, down from their previous estimate of ($0.87). The consensus estimate for Immunic’s current full-year earnings is ($0.92) per share. Brookline Capital Management also issued estimates for Immunic’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.03) EPS.

IMUX has been the topic of several other research reports. StockNews.com raised Immunic from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. Leerink Partners restated an “outperform” rating and set a $5.00 target price on shares of Immunic in a research report on Monday, September 9th. B. Riley started coverage on shares of Immunic in a report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $28.00 price objective on shares of Immunic in a report on Tuesday, July 16th. Finally, Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $11.20.

Immunic Price Performance

NASDAQ:IMUX opened at $1.59 on Friday. The business’s 50-day simple moving average is $1.51 and its two-hundred day simple moving average is $1.35. Immunic has a 52 week low of $0.95 and a 52 week high of $2.11. The stock has a market cap of $143.23 million, a PE ratio of -0.87 and a beta of 1.84.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same quarter in the prior year, the company earned ($0.54) EPS.

Institutional Investors Weigh In On Immunic

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IMUX. Virtu Financial LLC bought a new position in shares of Immunic during the 1st quarter valued at approximately $25,000. Ikarian Capital LLC raised its stake in shares of Immunic by 258.3% in the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after acquiring an additional 1,162,378 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Immunic by 100.7% in the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock worth $4,480,000 after acquiring an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Immunic during the 1st quarter worth about $9,266,000. Finally, BVF Inc. IL bought a new position in Immunic during the 1st quarter valued at about $11,752,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.